SQUAWK/NEWS
Account
Theme
Account
Menu
Live News EARNINGS FLASH L impact

BioNTech Drug Shows Modest PFS Improvement Versus Chemotherapy

Trastuzumab pamirtecan showed a modest progression-free survival improvement versus chemotherapy in HR+/HER2-low metastatic breast cancer.

Related stories